# Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery

> **NCT00327379** · PHASE3 · TERMINATED · sponsor: **Bayer** · enrollment: 54 (actual)

## Conditions studied

- Blood Loss, Surgical
- Postoperative Hemorrhage

## Interventions

- **DRUG:** Trasylol (Aprotinin, BAYA0128)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00327379
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02-27
- **Primary completion:** 2007-03-01
- **Final completion:** 2007-03-01
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2019-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00327379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00327379, "Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00327379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*